G20
Conditions
Interventions
Group 1: 65 Patients with Parkinson's Disease at baseline and 2-year-follow-up, samples of blood, urine and saliva, FDG-PET, F-DOPA-PET, resting state MRI, PANDA, MMST, BDI II, FOG-Q, NMS Scale, PDQ-3
Sponsors
Uniklinik KölnKlinik und Poliklinik für Neurologie
Eligibility
Sex/Gender
All
Age
55 Years to 80 Years
Inclusion criteria
Inclusion criteria: Patients with PD: A diagnosis of Parkinson's Disease meeting the British Brain Bank Criterias; Hoehn & Yahr I-II; A tolerable withdraw of 12 hours of non retarded dopaminergic medication or of 72 hours of retarded medication, respectivly; Age 55 - 80 y; Good command of german; Written informed consent Healthy controls: Age > 55 y; Written informed consent
Exclusion criteria
Exclusion criteria: Patients with PD: Existence of a disease which affect the cognition; Depression (BDI > 20 points); Dementia (PANDA 30) Healthy controls: Neurological diseases; treatment with drugs affecting the CNS, which cannot be withdrawed at least 12 hours before testing; Containdications for MRI: cardiac pacemaker, artificial cardiac valve, internal metalic objects, pregnancy, during the period of lactation, claustrophobia, adipositas (BMI > 30)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Identification and presentation of genetic and metabolomic changes and significantly changed connectivity in cerebral networks, which differ in between subtypes of parkinsons disease. We compare imaging data ([18F]FDG-PET,[18F]Dopa-PET,rsMRT) and clinical data of patients and healthy controls at baseline and of patients at baseline and 2-year-follow-up. | — |
Countries
Germany
Contacts
Public ContactKerstin Donner-Rosenwick
Klinik und Poliklinik für NeurologieUniklinik KölnAG Bewegungsstörung und Tiefe HirnstimulationStudienbüro
Outcome results
None listed